10/06/2014 - 4:36pm

In honor of the 75th anniversary of the company’s founding, Dollar General chairman and CEO Rick Dreiling and other senior leaders rang the opening bell Monday morning at the New York Stock Exchange.

10/06/2014 - 10:13am

Healthcare Distribution Management Association released a statement in support of the FDA’s “Know Your Source” campaign.

10/06/2014 - 9:46am

The Council for Responsible Nutrition on Monday urged the U.S. District Court in New Jersey to hold the Federal Trade Commission to the flexible “competent and reliable scientific evidence” standard for review of dietary supplement advertising.

10/01/2014 - 11:37am

California Governor Jerry Brown on Tuesday signed legislation for the nation's first statewide ban on single-use plastic bags at supermarkets, drug stores and select other retail outlets.

09/30/2014 - 12:55pm

Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the Food and Drug Administration approved Relistor (methylnaltrexone bromide) subcutaneous injection in 12-mg dosage strength to treat constipation in patients taking opioids for chronic, non-cancer pain. 

09/26/2014 - 2:25pm

Boehringer Ingelheim Pharmaceuticals announced that the Food and Drug Administration approved Spiriva Respimat (tiotropium bromide) inhalation spray as a treatment for bronchospasm associated with chronic obstructive pulmonary disease. 

09/26/2014 - 1:03pm

Actavis on Friday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine transdermal system, a generic version of Butrans from Purdue Pharma. 

09/25/2014 - 1:04pm

Celgene Corp. earlier this week announced that the Food and Drug Administration approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis. The drug is the first and only PDE4 inhibitor approved for the treatment of plaque psoriasis, according to the company.

09/25/2014 - 12:17pm

AbbVie on Thursday announced that the Food and Drug Administration approved Humira (adalimumab) as a treatment for pediatric Crohn's disease patients ages 6 years and older when other treatments haven't worked well enough.